Graft-versus-host disease (GVHD) is a common and severe complication that occurs after stem cell transplantation, where the ...
A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...
9h
GlobalData on MSNRegeneron’s macular oedema therapy shows promise in Phase III trialIn the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.
Experts from five states have sounded the alarm about blockbuster weight loss drugs like Ozempic leaving users blind, ...
Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.
The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...
The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.
Researchers have conducted one of the largest eye studies in the world to reveal new insights into retinal thickness, highlighting its potential in the early detection of diseases like type 2 diabetes ...
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...
Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results